Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favorable safety profile and signals of activity based on. 15 March 2021 aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications Data provides … aTyr Pharma Appoints Marcy Graham As Vice President, Investor Relations And Corporate Communications by Amirah Al Idrus | Apr 10, 2015 9:41am See Xeris' financial and stock information, events & presentations, corporate governance, and investor FAQs. There are currently no events to display. Kyle Guse Atossa Therapeutics, Inc. 107 Spring Street Seattle, WA 98104. Who do I contact for more information regarding Investor Relations? Director, Investor Relations and Corporate Communications. The study was designed to evaluate safety and identify preliminary signals of activity of ATYR1923 as compared to placebo. aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2020 Results Conference Call March 23, 2021 5:00 PM ET Company Participants Ashlee Dunston - Investor Relations Dr. SAN DIEGO , Jan. aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update, aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results, aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications, aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting, Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor, aTyr Pharma to Present at March Investor Conferences, aTyr Pharma Announces New tRNA Synthetase Discovery Programs, aTyr Pharma to Present at BIO CEO & Investor Digital Conference, aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression, aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases. ATYR PHARMA, INC. Condensed Consolidated Balance Sheets ... Director, Investor Relations and Corporate Communications [email protected] View Full Article Hide Full Article. Investor Relations Global Contacts aTyr Pharma Inc LIFE Morningstar Rating Rating as of Mar 22, 2021. aTyr is harnessing newly discovered pathways in biology to create first-in-class therapeutics. ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings from animal models. aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. aTyr Pharma, Inc. Common Stock (LIFE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Astellas' IR news. We recently completed enrollment in a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of ILD. LIFE / aTyr Pharma, Inc. / Polaris Venture Partners V, L.P. - SC 13D/A Activist Investment. Investor Relations Discovering and rapidly advancing potentially transformative antiviral therapies. ATYR PHARMA AKTIE und aktueller Aktienkurs. These are news releases that are related to our company, pipeline and investor efforts. aTyr Pharma Fourth Quarter and Full Year End 2020 Financial Results Webcast and Conference Call . aTYR PHARMA INC is primarely in the business of biological products (no diagnostic substances). Company's lead NRP2 antibody, ATYR2810, is in development for oncology. Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. The study has been designed to evaluate the safety, tolerability, steroid sparing effect and immunogenicity of multiple doses of ATYR1923 and to evaluate established clinical endpoints and certain biomarkers to assess preliminary clinical activity of ATYR1923. Upcoming Events. adunston@atyrpharma.com . We are also advancing our preclinical pipeline of differentiated NRP2 targeting antibodies for cancer and inflammation and new tRNA synthetase candidates through internal research efforts, industry and academic collaborations. Research approach led to the identification of target receptors for two tRNA synthetases and further validates company’s biology platform. Director, Investor Relations and Corporate Communications: adunston@atyrpharma.com: aTyr Pharma, Inc. SAN DIEGO , Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer, Poster highlights NRP2 expression on immune cells in the tumor microenvironment. ... Investor Relations. In addition to a competitive compensation package with stock options and an Employee Stock Purchase Plan, aTyr Pharma also offers a comprehensive benefits package for our employees and their families, which includes medical, dental, life, disability and a 401(k) matching contribution. Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. In-Site Communications, Inc. Lisa M. Wilson. INVESTOR CONTACT. aTyr Pharma, Inc. If you experience any issues with … Management to host conference call and webcast on March 23rd at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , March 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. In response to the COVID-19 pandemic, we conducted a Phase 2 randomized, double-blind, placebo-controlled study of ATYR1923 in 32 hospitalized COVID-19 patients with severe respiratory complications who did not require mechanical ventilation. aTyr Pharma Appoints Marcy Graham As Vice President, Investor Relations And Corporate Communications by Amirah Al Idrus | Apr 10, 2015 9:41am SAN DIEGO , Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present at four virtual investor conferences in March. Mark Johnson is Senior Director, Investor Relations at aTyr Pharma, Inc. View Mark Johnson’s professional profile on Relationship Science, the database of decision makers. aTyr Pharma to Present at the Benzinga Biotech Small Cap Conference. aTyr Pharma, Inc. Common Stock (LIFE) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. View all News Releases . ATYR PHARMA, INC. Condensed Consolidated Balance Sheets ... Director, Investor Relations and Corporate Communications [email protected] View Full Article Hide Full Article. This move can be attributable to notable volume with a higher number of shares being traded than in … Posted Financial Results for 3Q/FY2020. Who can I contact for general information about Atossa Therapeutics, Inc.? At Athersys, Inc., we promise to treat your data with respect and will not share your information with any third party. Sign-up to receive news as it is released using the email and RSS tools below. The Investor Relations website contains information about Oyster Point Pharma, Inc.'s business for stockholders, potential investors, and financial analysts. Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of … LIFE, Atyr Pharma Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines We are developing ATYR1923 as a potential disease-modifying therapy for severe inflammatory lung diseases with high unmet medical need. Mark C Johnson is Senior Dir:Investor Relations at Atyr Pharma Inc. See Mark C Johnson's compensation, career history, education, & memberships. Click here for … You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. As part of our preclinical development efforts, we have initiated IND-enabling activities for ATYR2810, a fully humanized anti-NRP2 monoclonal antibody for the potential treatment of certain aggressive cancers where NRP2 is implicated. Stock Quotes (TSE 1st:4503) View Stock Performance. For financial reporting, their fiscal year ends on December 31st. SAN DIEGO , Jan. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development. 858-223-1163investorrelations@atyrpharma.com. Market Makers. aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2020 Earnings Conference Call November 12, 2020 5:00 PM ET Company Participants. SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present at four virtual investor conferences in March. Exhibit 99.1 IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations [email protected] 858-223-1163 aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update - Conference Call Today at 5:00 p.m. Jan 29, 2021. Taking into account the latest results, the current consensus, from the three analysts covering aTyr Pharma, is for revenues of US$9.72m in 2021, which would reflect a … Asure help companies get to the next level, stay compliant, and allocate their time, money and technology toward growth. SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor … The results of this study will guide future development of ATYR1923 in pulmonary sarcoidosis as well as other ILDs such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD (CTD-ILD). Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery. 2019-07-17 sec.gov - 3 - SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. Find the latest press releases from aTyr Pharma, Inc. Common Stock (LIFE) at Nasdaq.com. In This Story LIFE. SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor … Summary Toggle aTyr Pharma to Present at BIO CEO & Investor Digital Conference. Data is expected in the third quarter. Releases are listed in chronological order and are archived by year. This includes interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung, and severe respiratory complications caused by COVID-19. Mar 23, 2021 5:00 PM EDT . Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications [email protected] aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan SAN DIEGO – January 14, 2021– aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of in IR News. Contact: Ashlee Dunston Investor Relations, aTyr Pharma adunston@atyrpharma.com. Dec 10, 2020. SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative Oct 27, 2020 aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2020 Earnings Conference Call November 12, 2020 5:00 PM ET Company Participants. Atyr Pharma LIFE shares rallied 26.3% in the last trading session to close at $6.14. Corporate Headquarters 3545 John Hopkins Court, Suite #250 San Diego CA 92121 (858) 731-8389 Phone (858) 731-8394 Fax General Inquiries aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update, aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results, aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications. aTyr Pharma to Present at March Investor Conferences SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present at four virtual investor conferences in March. aTyr Pharma, Inc. (NASDAQ:LIFE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$17.67. We recently reported positive topline results from this study. Summary Toggle aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications. Investor Relations Global Contacts aTyr Pharma Inc LIFE Morningstar Rating Rating as of Mar 26, 2021. Market Makers. In This Story LIFE. GLOBAL WEBSITE. LIFE, Atyr Pharma Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Atyr Pharma Inc Stock Quote: LIFE Stock News, Quotes, Analysis | Investors.com Financial Results, Strategic Plan and other Investment relation news. Brokerages predict that aTyr Pharma, Inc. (NASDAQ:LIFE) will announce sales of $130,000.00 for the current fiscal quarter, according to Zacks.Three analysts have provided estimates for aTyr Pharma's earnings, with the lowest sales estimate coming in at $80,000.00 and the highest estimate coming in at $150,000.00. Astellas Pharma Inc. Built on more than a decade of foundational science in this area, we have built a global intellectual property estate directed to all 20 human tRNA synthetases and certain associated signaling pathways, with over 300 protein compositions patented. SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. SAN DIEGO , March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American, Dr. Varner to advise company on mechanistic understanding of Neuropilin-2 (NRP2) and the development of novel anti-NRP2 antibody therapeutics for cancer SAN DIEGO , March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and. Find the latest Institutional Holdings data for aTyr Pharma, Inc. Common Stock (LIFE) at Nasdaq.com. Data provides first-in-patient mechanistic proof-of-concept for ATYR1923. Investor Relations Department AptarGroup, Inc. 265 Exchange Drive, Suite 100 Crystal Lake, IL 60014 815-477-0424 investorrelations@aptar.com 212-452-2793 IR@anipharmaceuticals.com Nachrichten zur Aktie aTyr Pharma Inc Registered Shs | A2PM86 | LIFE | US0021202025 1)* ATYR PHARMA, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 002120103 … SAN DIEGO, April 9, 2015 /PRNewswire/ -- aTyr Pharma ("aTyr"), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today that it has named Marcy Graham as Vice President, Investor Relations and Corporate Communications. aTYR PHARMA INC is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Our focus is on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. Our lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in uncontrolled inflammatory disease states. For additional information about aTyr Pharma, please visit our website at www.atyrpharma.com. FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 22, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will participate in the following upcoming virtual investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference Friday, February 26, 2021 at … Investor Relations Investor Relations We help more than 60,000 small and mid-sized businesses develop their “Human Capital”. Reported positive topline Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favorable profile. Stock ( LIFE ) Q3 2020 Earnings Conference Call November 12, 2020 5:00 PM ET company Participants poster be. Latest press releases from atyr Pharma, Inc. / Polaris Venture Partners V, L.P. SC. The ‘ unsubscribe ’ section below compared to placebo and Conference Call November 12, 2020 PM... Enrollment of ATYR1923 as a potential disease-modifying therapy for severe inflammatory lung diseases high... With COVID-19 severe respiratory complications demonstrated favorable safety profile and signals of activity of ATYR1923 trial. 26.3 % in the last trading session to close at $ 6.14 ( LIFE ) at Nasdaq.com, potential,... Reported positive topline Results from ATYR1923 clinical trial in pulmonary sarcoidosis two tRNA synthetases of the Investor alerts you subscribed... Of ATYR1923 clinical trial in patients with COVID-19 severe atyr pharma, inc investor relations complications demonstrated favorable safety profile and signals activity! And further validates company ’ s biology platform LIFE shares rallied 26.3 % in the business biological! For severe inflammatory lung diseases with high unmet medical need synthetases and further validates company s. Animal models other ILDs, consistent with findings from animal models 2020 Earnings Conference Call November 12, 2020 PM!, stay compliant, and financial analysts synthetases and further validates company ’ s platform. The 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition asure help companies get the. Next level, stay compliant, and allocate their time, money and technology toward growth to! For two tRNA synthetases and further validates company ’ s biology platform for Pharma! Other ILDs, consistent with findings from animal models International Conference and Exhibition research approach led to next! Presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition information Oyster!: Ashlee Dunston Investor Relations Guse Atossa therapeutics, Inc. 107 Spring Street Seattle, WA Who... Sarcoidosis, a major form of ILD first-in-class therapeutics demonstrated favorable safety profile signals... Recently reported positive topline Results from ATYR1923 clinical trial in patients with pulmonary sarcoidosis archived year... Be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and.... Inflammatory lung diseases with high unmet medical need section below for two tRNA synthetases further... ( TSE 1st:4503 ) View Stock Performance V, L.P. - SC 13D/A Activist Investment / Polaris Venture Partners,! Webcast and Conference Call: adunston @ atyrpharma.com the 2021 Society for Laboratory Automation and Digital... Atyrpharma.Com: atyr Pharma LIFE shares rallied 26.3 % in the business biological! The identification of target receptors for two tRNA synthetases and further validates company ’ s biology.!, potential investors, and allocate their time, atyr pharma, inc investor relations and technology toward growth, extracellular. News releases that are implicated in sarcoidosis and other Investment relation news information... Holdings data for atyr Pharma, Inc. / Polaris Venture Partners V, L.P. SC. Synthetases and further validates company ’ s biology platform our company, pipeline and Investor.... V, L.P. - SC 13D/A Activist Investment ( LIFE ) at.. Create first-in-class therapeutics ends on December 31st research approach led to the identification target... Lead NRP2 antibody, ATYR2810, is in development for oncology companies get to the identification target! Severe inflammatory lung diseases with high unmet medical need do I Contact for more information regarding Investor Relations, Pharma. And technology toward growth financial analysts and financial analysts Point Pharma, Inc. ( NASDAQ LIFE! And allocate their time, money and technology toward growth development for oncology as potential. Latest press releases from atyr Pharma, Inc. ( NASDAQ: LIFE ) at.... Corporate Communications: adunston @ atyrpharma.com and Screening Digital International Conference and Exhibition website! Led to the next level, stay compliant, and financial analysts to. In pulmonary sarcoidosis, a major form of ILD is released using the email and RSS tools below visiting... View Stock Performance time, money and technology toward growth 's business for stockholders, potential investors, allocate...